More Human BM-MSC With Similar Subpopulation Composition and Functional Characteristics Can Be Produced With a GMP-Compatible Fabric Filter System Compared to Density Gradient Technique

Background Mesenchymal stromal cells (MSCs), multipotent progenitors that can be isolated from a variety of different tissues, are becoming increasingly important as cell therapeutics targeting immunopathologies and tissue regeneration. Current protocols for MSC isolation from bone marrow (BM) rely on density gradient centrifugation (DGC), and the production of sufficient MSC doses is a critical factor for conducting clinical MSC trials. Previously, a Good Manufacturing Practice (GMP)–compatible non-woven fabric filter device system to isolate MSCs was developed to increase the MSC yield from the BM. The aim of our study was to compare high-resolution phenotypic and functional characteristics of BM-MSCs isolated with this device and with standard DGC technology. Methods Human BM samples from 5 donors were analyzed. Each sample was divided equally, processing by DGC, and with the filter device. Stem cell content was assessed by quantification of colony-forming units fibroblasts (CFU-F). Immunophenotype was analyzed by multicolor flow cytometry. In vitro trilineage differentiation potential, trophic factors, and IDO-1 production were assessed. Functionally, immunomodulatory potential, wound healing, and angiogenesis were assayed in vitro. Results The CFU-F yield was 15-fold higher in the MSC preparations isolated with the device compared to those isolated by DGC. Consequently, the MSC yield that could be manufactured at passage 3 per mL collected BM was more than 10 times higher in the device group compared to DGC (1.65 × 109 vs. 1.45 × 108). The immunomodulatory potential and IDO-1 production showed donor-to-donor variabilities without differences between fabric filter-isolated and DGC-isolated MSCs. The results from the wound closure assays, the tube formation assays, and the trilineage differentiation assays were similar between the groups with respect to the isolation method. Sixty-four MSC subpopulations could be quantified with CD140a+CD119+CD146+ as most common phenotype group, and CD140a+CD119+CD146+MSCA-1–CD106–CD271– and CD140a+CD119+CD146–MSCA-1–CD106–CD271– as most frequent MSC subpopulations. As trophic factors hepatocyte growth factor, epidermal growth factor, brain-derived neurotrophic factor, angiopoietin-1, and vascular endothelial growth factor A could be detected in both groups with considerable variability between donors, but independent of the respective MSC isolation technique. Conclusion The isolation of MSCs using a GMP-compatible fabric filter system device resulted in higher yield of CFU-F, producing substantially more MSCs with similar subpopulation composition and functional characteristics as MSCs isolated by DGC.

[1]  A. Kretschmer,et al.  Modulating endothelial adhesion and migration impacts stem cell therapies efficacy , 2020, EBioMedicine.

[2]  A. Kretschmer,et al.  Cell motility and migration as determinants of stem cell efficacy , 2020, EBioMedicine.

[3]  D. Stroncek,et al.  Human Mesenchymal Stromal Cell (MSC) Characteristics Vary Among Laboratories When Manufactured From the Same Source Material: A Report by the Cellular Therapy Team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative , 2020, Frontiers in Cell and Developmental Biology.

[4]  M. Grumet,et al.  Trends in mesenchymal stem cell clinical trials 2004‐2018: Is efficacy optimal in a narrow dose range? , 2019, Stem cells translational medicine.

[5]  K. Bieback,et al.  Gaps in the knowledge of human platelet lysate as a cell culture supplement for cell therapy: A joint publication from the AABB and the International Society of Cell Therapy. , 2019, Cytotherapy.

[6]  K. Bieback,et al.  Production and quality testing of multipotent mesenchymal stromal cell therapeutics for clinical use , 2019, Transfusion.

[7]  Peter Bader,et al.  Molecular signature of human bone marrow-derived mesenchymal stromal cell subsets , 2019, Scientific Reports.

[8]  Matthias M. Aitzetmüller,et al.  Single‐Cell Transcriptomics of Human Mesenchymal Stem Cells Reveal Age‐Related Cellular Subpopulation Depletion and Impaired Regenerative Function , 2018, Stem cells.

[9]  D. Strunk,et al.  Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  D. Bueno,et al.  The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review , 2018, Front. Immunol..

[11]  M. Longaker,et al.  Mesenchymal Stromal Cells and Cutaneous Wound Healing: A Comprehensive Review of the Background, Role, and Therapeutic Potential , 2018, Stem cells international.

[12]  K. Swiech,et al.  Mesenchymal Stromal Cells: From Discovery to Manufacturing and Commercialization , 2018, Stem cells international.

[13]  G. Lucchini,et al.  Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM) , 2018, Bone Marrow Transplantation.

[14]  M. Pittenger,et al.  Corrigendum to: Concise Review: MSC‐Derived Exosomes for Cell‐Free Therapy , 2017, Stem cells.

[15]  K. Tarte,et al.  Brief Report: Proteasomal Indoleamine 2,3‐Dioxygenase Degradation Reduces the Immunosuppressive Potential of Clinical Grade‐Mesenchymal Stromal Cells Undergoing Replicative Senescence , 2017, Stem cells.

[16]  F. Rodeghiero,et al.  Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future , 2016, Stem Cell Research & Therapy.

[17]  R. Schäfer,et al.  Mesenchymal Stem/Stromal Cells in Regenerative Medicine: Can Preconditioning Strategies Improve Therapeutic Efficacy , 2016, Transfusion Medicine and Hemotherapy.

[18]  T. Bliss,et al.  High-Resolution Microfluidic Single-Cell Transcriptional Profiling Reveals Clinically Relevant Subtypes among Human Stem Cell Populations Commonly Utilized in Cell-Based Therapies , 2016, Front. Neurol..

[19]  Huey-Kang Sytwu,et al.  CD146+ mesenchymal stem cells display greater therapeutic potential than CD146– cells for treating collagen-induced arthritis in mice , 2016, Stem Cell Research & Therapy.

[20]  T. Klingebiel,et al.  In vitro migration and proliferation (“wound healing”) potential of mesenchymal stromal cells generated from human CD271+ bone marrow mononuclear cells , 2015, Journal of Translational Medicine.

[21]  E. Jones,et al.  Where is the common ground between bone marrow mesenchymal stem/stromal cells from different donors and species? , 2015, Stem Cell Research & Therapy.

[22]  Alan Trounson,et al.  Stem Cell Therapies in Clinical Trials: Progress and Challenges. , 2015, Cell stem cell.

[23]  H. Northoff,et al.  Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells , 2013, BMC Medicine.

[24]  H. Northoff,et al.  Mesenchymal stromal/stem cells markers in the human bone marrow. , 2013, Cytotherapy.

[25]  T. Olson,et al.  Improved isolation and expansion of bone marrow mesenchymal stromal cells using a novel marrow filter device. , 2013, Cytotherapy.

[26]  P. Giannoudis,et al.  Transcriptional profile of native CD271+ multipotential stromal cells: evidence for multiple fates, with prominent osteogenic and Wnt pathway signaling activity. , 2012, Arthritis and rheumatism.

[27]  T. Redmer,et al.  Replicative aging and differentiation potential of human adipose tissue-derived mesenchymal stromal cells expanded in pooled human or fetal bovine serum. , 2012, Cytotherapy.

[28]  P. Giannoudis,et al.  Single-platform quality control assay to quantify multipotential stromal cells in bone marrow aspirates prior to bulk manufacture or direct therapeutic use. , 2012, Cytotherapy.

[29]  F. Fagioli,et al.  Multipotent Mesenchymal Stromal Stem Cell Expansion by Plating Whole Bone Marrow at a Low Cellular Density: A More Advantageous Method for Clinical Use , 2011, Stem cells international.

[30]  R. Henschler,et al.  CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties , 2010, Haematologica.

[31]  S. Kimura,et al.  A novel method to isolate mesenchymal stem cells from bone marrow in a closed system using a device made by nonwoven fabric. , 2010, Tissue engineering. Part C, Methods.

[32]  F Beaujean,et al.  Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. , 2005, The Journal of bone and joint surgery. American volume.

[33]  M. Pittenger,et al.  Unraveling the Mesenchymal Stromal Cells' Paracrine Immunomodulatory Effects. , 2016, Transfusion medicine reviews.

[34]  J. Galipeau The mesenchymal stromal cells dilemma--does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? , 2013, Cytotherapy.

[35]  A. Ho,et al.  Isolation of human mesenchymal stromal cells is more efficient by red blood cell lysis. , 2008, Cytotherapy.

[36]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[37]  ANTHONY WREN,et al.  Population Growth , 1972, Nature.